Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moleculin Biotech, Inc.MBRX · Entity 7886 | Director | November 12, 2025 | November 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moleculin Biotech, Inc.
Report date November 12, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.49 · Expires 2035-11-12 | Direct | 164,001 |
Reported balance
After 2025-11-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-12 · Grant · Acquired 150,000 · Balance 164,001 F2: The options were issued in connection with the reporting person's Board of Director service to the Company. F1: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.
F2: The options were issued in connection with the reporting person's Board of Director service to the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Checkmate Pharmaceuticals, Inc.
Report date May 31, 2022 · Filed May 31, 2022
Section 16 reporting ended · disclosed 2022-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.12 · Expires 2031-12-16 | Direct | 0 |
Reported balance
After 2022-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-31 · Disposition to issuer · Disposed 20,061 · Balance 0 F1: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 12, 2025 Filed Nov 14, 2025 16:07 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock Options (right to buy) · Derivative | 150,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0001437749-25-035179 · rdgdoc.xml · derivative · entry 1 Yan Joy · CIK 0001866109 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,001 Underlying: Common Stock · 150,000 shares Expires 2035-11-12 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 20:06 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001437749-24-033710 · rdgdoc.xml · derivative · entry 1 Yan Joy · CIK 0001866109 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,001 Underlying: Common Stock · 10,000 shares Expires 2034-11-04 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest through April 2025, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| May 25, 2023 Filed May 26, 2023 17:16 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $0.62 | Not disclosed |
DisclosureSEC source: 0001437749-23-016005 · rdgdoc.xml · derivative · entry 1 Yan Joy · CIK 0001866109 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-25 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest on the earlier of one year from the date of the Company's 2023 annual meeting of stockholders or on the next annual meeting of stockholders, subject to the grantee's continued service on the Company's Board of Directors on such vesting date. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 19:02 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $1.49 | Not disclosed |
DisclosureSEC source: 0001437749-22-015658 · rdgdoc.xml · derivative · entry 2 Yan Joy · CIK 0001866109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-20 F3 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F2 · derivative.exercise_date: The options set forth in this table vest on the earlier of one year from the date of the Company's 2022 annual meeting of stockholders or on the date of the next annual meeting of stockholders, subject the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 19:02 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 23,333 | Not disclosed Strike: $1.49 | Not disclosed |
DisclosureSEC source: 0001437749-22-015658 · rdgdoc.xml · derivative · entry 1 Yan Joy · CIK 0001866109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 23,333 shares Expires 2032-06-20 F3 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| May 31, 2022 Filed May 31, 2022 10:06 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,061 | Not disclosed Strike: $3.12 | Not disclosed |
DisclosureSEC source: 0000899243-22-020084 · doc4.xml · derivative · entry 1 Yan Joy · CIK 0001866109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,061 shares Expires 2031-12-16 F1 · kind: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes. F1 · price: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes. F1 · derivative.exercise_date: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:48 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock Option (right to buy) · Derivative | 6,667 | Not disclosed Strike: $1.38 | Not disclosed |
DisclosureSEC source: 0001437749-22-005081 · rdgdoc.xml · derivative · entry 1 Yan Joy · CIK 0001866109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2032-03-01 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 20:22 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | GrantStock Option (Right to Buy) · Derivative | 20,061 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0000899243-21-048892 · doc4.xml · derivative · entry 1 Yan Joy · CIK 0001866109 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,061 Underlying: Common Stock · 20,061 shares Expires 2031-12-16 F1 · derivative.exercise_date: This stock option shall vest 1/3 on the first anniversary of the grant date and monthly thereafter through the third anniversary of the grant date, subject to the Reporting Persons continued service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.